COVID-19 Infection and Primary Graft Failure in a Pediatric
Hematopoietic Stem Cell Transplant Patient
Currently, data on the effects of the novel Coronavirus disease
(COVID-19) on hematopoietic stem cell transplant (HSCT) recipients is
limited. In this case, an 8-year-old male with IPEX syndrome underwent
allogeneic HSCT and was found COVID-19 positive 23 days post-transplant.
He was treated with a 10-day course of remdesivir, three doses of
tocilizumab, and two units of COVID-19 convalescent plasma (CCP).
Initially, inflammatory markers decreased with treatment. However, he
experienced primary graft failure, most likely secondary to COVID-19
infection, developed multiple systemic infections, and subsequently died
before a second graft infusion could be administered.